SGLT2 inhibitor is kidney protective, even if eGFR <30 - PACE-CME

SGLT inhibitor is kidney protective even if eGFR

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Disease-modifying effects of finerenone in CKM syndrome
Disease-modifying effects of finerenone in CKM syndrome
ESC Congress 2024
Disease-modifying effects of finerenone in CKM syndrome
- Muthiah Vaduganathan, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
Management of patients with CKD and HF complicated by hyperkalemia
Management of patients with CKD and HF complicated by hyperkalemia
Kidney Disease
Management of patients with CKD and HF complicated by hyperkalemia
- Ellie Kelepouris, MD
- Stephen J. Greene, MD
The key role of RAASi therapy in patients with HF
The key role of RAASi therapy in patients with HF
Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy
The key role of RAASi therapy in patients with HF
- Shelley Zieroth, MD